[Oral enoximone therapy as a therapeutic bridging before heart transplantation].
A 58-year-old male patient with end-stage cardiomyopathy suffered from cardiac decompensation under parenteral catecholamine medication. Oral therapy with 450 mg Enoximone daily achieved recovery after 4 weeks, so that an orthotopic cardiac transplantation could be performed. The postoperative outcome was uneventful. Selective phosphodiesterase-inhibitors help to fill a therapeutic gap in the management of catecholamine-refractory heart failure.
Zeplin
H E
HE
Klinik für Thorax-, Herz- und Gefässchirurgie, Fulda.
Stegmann
T
T
Fell
J J
JJ
Dressler
H T
HT
Dieterich
H A
HA
D000284:Administration, Oral; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D004452:Echocardiography; D017335:Enoximone; D016027:Heart Transplantation; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D011300:Preoperative Care; D012770:Shock, Cardiogenic / Q000188:drug therapy
D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone
Orales Enoximon--Therapie als Uberbrückung vor Herztransplantation.